24 August 2016 in Hematology
JIJosé Luis Iglesias-Benavides
José Luis Iglesias-Benavides
+6
Objective: To compare serum ferritin (SF) concentrations and other hematological parameters between patients with preeclampsia (PE) and normal pregnant women of the same gestational period who received supplemental iron during pregnancy. Methods: Prospective, comparative, observational pilot study that included 31 women with PE and 30 healthy pregnant women, at 20 weeks’ of gestation. Ferritin, iron and complete blood cell count were compared between groups. Results: In comparison with controls, preeclamptic patients had a higher weight, body mass index, and arterial pressure. Serum ferritin and serum iron were higher in patients with PE (median: 36.5 μg/l vs. 20.9 μg/l and 103.9 μg/dl vs. 90.8 μg/dl) with a significant difference (P = 0.019 and P = 0.345). SF values >40 μg/l correlated with PE (r = 0.281; P = 0.032). A platelet count less than 100 × 109/l was higher in the PE group than in the control group (13% vs. 3%, P = 0.354). Conclusion: Higher SF levels, despite being within normal range, were associated with PE. The incidence of thrombocytopenia was higher in preeclamptic women, however, the remaining hematological parameters were similar in both groups.
1 September 2021 in Microbial Pathogenesis
OFOrlando E. Flores-Maldonado
Orlando E. Flores-Maldonado
+5
13 September 2025 in Transplantation and Cellular Therapy
Hematopoietic stem cell transplantation (SCT) offers curative potential for hematologic diseases but demands rigorous quality management often out of reach in low- and middle-income countries (LMICs). Our institution- the only public academic hospital in Latin America accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) since 2016, with recertifications in 2020 and 2024-has demonstrated that FACT standards can be met through pragmatic, cost-effective adaptations. This review summarizes key strategies for continued maintenance of high-quality transplantation practices, including data management, continuous medical education, as well as cost-effective clinical practices. We also address donor selection approaches, cryopreservation alternatives, and supplementary accreditations. By outlining our FACT accreditation journey and outcomes equivalent to conventional settings, we provide a replicable framework for LMIC centers to achieve international quality benchmarks. Our experience underscores that high-quality SCT and sustained accreditation are attainable in resource-constrained environments, ultimately improving access and survival for patients across the LMICs.
1 April 2025 in JCO Global Oncology
AHAna K. Hernández-Navarro
+5
PURPOSE: To validate and replicate an automated decentralized CD19 chimeric antigen receptor T (CAR-T) cell manufacturing process from healthy adult volunteers in an academic institution in a middle-income country. METHODS: Healthy volunteers were recruited and underwent leukapheresis with the continuous mononuclear cell (MNC) collection protocol. Clinical-grade CAR-T cell manufacturing was performed in a closed system using a second-generation CD19 vector with 41BB costimulatory domain. Quality control was assessed at different points in the production process with prespecified release criteria including product's aspect, sterility, cell viability, impurity, and quantity. The target dose formulation was 1 × 10 6 /kg viable CAR-T cells per volunteer. RESULTS: Five healthy volunteers were recruited, all donated adequate MNC units, and successfully underwent the manufacturing process. After T-cell culture harvest, the products contained a median CAR-T cell concentration of 16.5 × 10 6 /mL (range, 7.7-22.2 × 10 6 /mL), with a median transduction percentage of 44.7% (range, 39.2%-60.5%) and a median CD3 + cell viability of 97.7% (range, 90.4%-98.7%). Sterility was maintained throughout the manufacturing process. The quantity of cells harvested per kilogram of body weight was 24.6 MB-CART19.1 cells × 10 6 /kg (range, 9.3-33.1 × 10 6 /mL). The quality was similar in both fresh and cryopreserved units. Dose formulations were 1.1 CAR-T cells × 10 6 /kg (range, 1.0-1.2 CAR-T cells × 10 6 /kg). CONCLUSION: Our study demonstrates an effective methodology with satisfactory and comparable performance to international reports. Point-of-care manufacturing is a feasible alternative to increase access to CAR-T cells in academic centers.
26 October 2021 in American Journal of Clinical Pathology
Objectives: To assess the efficacy of a method to circumvent CD20-positive antigen masking by rituximab for flow cytometry analysis of B-cell malignancies in hematology patients. Methods: Mononuclear cells (MNCs) from 10 healthy individuals and 5 untreated patients with B-cell malignancies were sensitized with rituximab. Patients’ diagnoses included chronic lymphocytic leukemia, hairy cell leukemia, and follicular lymphoma. MNCs were isolated by gradient density centrifugation. An EDTA/glycine acid (EGA) elution method was used to dissociate CD20-rituximab complexes; afterwards, CD20-positive immunoreactivity was assessed by flow cytometry. A saturation curve was built based on serial dilutions of rituximab. Median fluorescent intensities of CD20-positive signals were obtained before sensitization with rituximab and after its elution with EGA. Results: CD20-positive signals were not detectable by flow cytometry after rituximab sensitization of B cells. CD20-sensitized vs CD20-unsensitized, CD20-sensitized vs CD20-eluted, and CD20-eluted vs CD20-negative control (NC) MNC populations exhibited statistical differences (P = .001), while CD20-sensitized vs CD20-NC populations did not (P = .499), confirming CD20 antigen masking by rituximab. Conclusions: Rituximab interfered with the flow cytometry protocol for CD20 determination on normal and neoplastic B cells. The EGA method efficiently eluted rituximab, allowing for accurate identification of CD20-positive B cells.
16 July 2026 in Blood Global Hematology
JFJuan P. Flores-Gutiérrez
DGDiego E. González-Ibarra
+7